ThomasNet Home   |   Promote Your Business
Home  |   My ThomasNet News®  |   Industry Market Trends  |   Submit Release  |   Advertise  |   About Us May 26, 2012  

Share Issue Gives Cellectricon SEK 89 Million to Continue Its Rapid Market Expansion

Print | 
Email |  Comment   Share  

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)

Cellectricon AB
Fabriksgatan 7
Gotheburg, 412 50
Sweden



Press release date: February 21, 2008

GOTHENBURG, Sweden, February 21 -- With two successful international product launches, Swedish biotech firm Cellectricon is entering a new expansion phase. The share issue will strengthen Cellectricon's financial capacity prior to a number of significant product launches in 2008-2009. These products have been developed in close collaboration with leading global pharmaceutical companies to meet the industry's increasing demand for fully automated, highly efficient systems for pre-clinical pharmaceutical development.

"Cellectricon is now entering a new expansion phase, in which the company will soon launch two large-scale systems that will revolutionize drug discovery. This capital will enable us to continue our rapid expansion in the United States, Europe, and Asia," said Dr. Mattias Karlsson, Cellectricon's CEO.

In 2008 Cellectricon will launch the first of their large-scale screening system, Cellaxess®HT, which has been developed in close cooperation with one of the world's largest pharmaceutical companies. Cellaxess®HT will be the only system on the market that enables large-scale supply of genetic material for cells and is tailor made for high throughput RNAi screening.

About Cellectricon

Cellectricon AB is a Swedish biotech company that is a successful provider of groundbreaking products to the pharmaceutical industry that increase efficiency in pre-clinical pharmaceutical development. Cellectricon has already successfully launched two products onto the market that have been sold to ten of the 12 largest pharmaceutical companies in the world. In 2007 the company increased its revenue by almost 50%. In 2008-2009 launch the high-performance systems Cellaxess®HT for RNAi screening and Dynaflow®HT for ion channel screening. Cellectricon's forthcoming products address a market that is estimated to be US $1.4 billion by 2010.

Source: Cellectricon AB

For more information, contact: Susanne Fagerlund VP Market Communications Telephone: +46(0)31-760-35-15 E-mail: susanne.fagerlund@cellectricon.com
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



Start Your Free
Subscription to
Industry Market Trends.
 More New Product News from this company:
Pharmaceutical System performs ion channel drug screening.
More ....
 Other News from this company:
Cellectricon Announces World's First System for High Throughput RNAi Screening
More ....
 Tools for you
Watch Company 
Company web site
More news from this company
E-Mail Story
Save Story


Home  |  My ThomasNet News®  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2012 Thomas Publishing Company
Terms of Use - Privacy Policy



Error close

Please enter a valid email address